Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Stays Firm On India Plans After Gleevec: An Interview With India Vice Chairman Ranjit Shahani

This article was originally published in PharmAsia News

Executive Summary

Novartis has been at the center of a long patent controversy, and although it recently faced an adverse ruling, India Vice Chairman Ranjit Shahani’s optimism about the Indian market is unshaken.

Advertisement

Related Content

Novartis Designs “Arogya Parivar” To Reach Real India In Its Rural Centers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC083978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel